Altruist Biologics' Landmark License Signals China's Biomanufacturing Rise

HANGZHOU, China – April 08, 2026 – In a move that underscores China's rapidly advancing role in the global biopharmaceutical supply chain, Altruist Biologics has secured a landmark commercial manufacturing license for its massive Hangzhou facility. The Chinese National Medical Products Administration (NMPA) granted the company a Drug Product Manufacturing License, known as a 'C Certificate,' for its 20,000-liter scale operations.

This approval is the first of its kind awarded to a biologics facility in China operating at this scale, marking a pivotal moment for both Altruist, a subsidiary of Innovent Biologics, and the country's burgeoning contract development and manufacturing organization (CDMO) sector. The licensure validates that the facility's advanced technologies and rigorous quality systems meet the stringent requirements for commercial drug production, positioning it as a key hub for large-scale manufacturing of life-saving therapies.

A New Scale for China's CDMO Ambitions

The certification specifically covers the facility's four 20,000-liter stainless steel bioreactors, which are the first and largest of their kind to be commissioned in China. This initial 80,000-liter capacity is just the beginning; upon completion, the Hangzhou site is slated to hold a total capacity of 172,000 liters. This expansion is a direct response to the soaring global demand for biologics, including monoclonal antibodies and fusion proteins, which require substantial manufacturing volume for commercial supply.

Altruist's move is part of a broader trend within China's biopharmaceutical industry. Driven by regulatory reforms like the Marketing Authorization Holder (MAH) system, which allows drug developers to outsource production, the domestic CDMO market is experiencing explosive growth. The NMPA's recent pilot programs to allow segmented manufacturing—a departure from the previous requirement for end-to-end production in a single facility—are further fueling this expansion by aligning Chinese regulations with international practices.

This has created a competitive landscape where capacity is king. While established players like WuXi Biologics have long dominated the market, Altruist's new large-scale, NMPA-certified facility establishes it as a formidable competitor. The sheer scale is critical, as industry experts project that China will need over 100,000 liters of additional biologics manufacturing capacity annually to support its maturing drug pipeline and serve international clients.

Setting a New Benchmark for Quality and Speed

Beyond the impressive scale, the speed at which Altruist Biologics achieved this milestone is turning heads. The company secured the C Certificate in just two months following facility qualification, an exceptionally rapid timeline for a complex biologics plant. This achievement speaks volumes about the maturity of its quality management systems and its deep regulatory expertise.

This is not an isolated success. Altruist has built a formidable track record of adherence to the industry's most rigorous international standards. The company has successfully passed 30 regulatory inspections, including audits by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its existing Suzhou site, with a 60,000-liter capacity, already meets global standards, allowing it to manufacture products for markets in the United States, Europe, and Japan. To date, the CDMO has supported the successful commercialization of eight different products.

This proven history of global compliance was undoubtedly a factor in the swift NMPA approval. It demonstrates that Altruist's facilities are not just built for the Chinese market but are designed from the ground up to be globally competitive, a crucial selling point for international pharmaceutical companies looking to secure their supply chains and access the Asian market.

Accelerating Patient Access to Next-Generation Therapies

Ultimately, the significance of this expanded capacity extends far beyond corporate milestones and market dynamics. The ability to produce biologics at such a large scale has a direct impact on the accessibility and affordability of modern medicines. Large-scale manufacturing can help alleviate production bottlenecks that often delay the launch of new drugs, reduce per-unit production costs, and accelerate the delivery of therapies to patients worldwide.

The Hangzhou facility is also equipped to handle the next generation of complex biotherapeutics. It features a standalone bioconjugation facility designed to produce antibody-drug conjugates (ADCs) and other complex molecules. ADCs, which combine the targeting ability of antibodies with the potent cell-killing effects of chemotherapy drugs, are among the most promising new treatments for cancer but are notoriously complex and costly to manufacture. By providing dedicated, large-scale capacity for these therapies, Altruist is helping to overcome a critical barrier in the fight against cancer.

This integrated, end-to-end service model—from cell line development to aseptic fill-finish for a wide range of biologics—offers a streamlined path for drug developers, particularly smaller biotech firms that lack their own manufacturing infrastructure. By partnering with a capable CDMO like Altruist, these innovators can focus on discovery and clinical development while ensuring a clear and efficient path to commercial production.

A Strategic Play in a Global Biopharma Vision

The expansion of Altruist Biologics is a cornerstone of the strategic vision of its parent company, Innovent Biologics. Innovent has been on a mission to evolve from a domestic biotech leader into a fully integrated, world-class biopharmaceutical company with a global footprint. Having a powerful, in-house CDMO arm serves a dual purpose in this ambition.

Internally, Altruist provides Innovent with the secure, large-scale manufacturing capacity needed to support its own rapidly growing pipeline of innovative drugs. This reduces reliance on third-party contractors, lowers costs, and gives Innovent greater control over its product supply chain. Externally, Altruist functions as a robust, revenue-generating business that leverages its expertise to serve a global client base, further diversifying Innovent's market presence.

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, commented on the achievement, stating, "We're pleased that our Hangzhou facility successfully achieved the C Certificate for biologics commercial manufacturing. This represents another remarkable milestone in our efforts to establish premier-quality operations and fully integrated services to support our clients' commercialization goals." His statement reinforces this vision of global service. "We look forward to supporting the development and manufacture of more life-saving treatments for our global clients to benefit patients worldwide."

Building on this foundation of accumulated expertise and advanced technology, Altruist Biologics is poised to continuously enhance its capabilities. The company's focus remains on providing flexible, cost-effective services that empower clients to navigate manufacturing hurdles and accelerate the journey of their life-saving therapies from the laboratory to patients who need them most.